期刊文献+

克罗恩病内科治疗的新进展 被引量:3

Advances in medical treatment of Crohn's disease
下载PDF
导出
摘要 对于活动期克罗恩病(CD)的治疗,日本是以营养疗法为首选;欧美则根据随机对照试验(RCF)的结果以类固醇激素为主,其差异可能与治疗期间,胃肠道营养剂的组成,QOL(生活质量)以及医疗保险制度等不同有关.近年来开发出较以往常用药物(柳氮磺胺吡啶及强的松)副作用少的新制剂.此外,根据疾病的具体情况,可以选择抗 CD4抗体;抗 TNF-α抗体;外源性给予 IL-10;抗粘附分子疗法;白细胞去除疗法;免疫调节疗法;肝素抗凝,EPA 等疗法.
作者 韩英 李世荣
出处 《世界华人消化杂志》 CAS 2000年第11期1269-1272,共4页 World Chinese Journal of Digestology
关键词 Crohm病 治疗 胃肠外营养 免疫抑制剂 Subject headings randomized controlled trials Crohns disease/therapy parenteral nutrition,total parenteral nutrition,home total immunosuppressive agents cell adhesion molecular
  • 相关文献

参考文献46

  • 1[2]Hanaauer SB,Meyers S Management of Crohn's disease in adults.Am J Gastroenterol,1997;92:559-566
  • 2[4]Seo M,Okada M,Yao T.The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease [ see comments].J Clin G astroenterol,1999 ;29:270 - 275
  • 3[5]Hen PD,Burke A,Baldassano RN.Nutrition and inflammatory bowel disease.Gastroenterol Clin North Am,1999;28:423-443
  • 4[6]Husain A,Korzenik JR.Nutritional issues and therapy in inflammatory bowel disease.Semin Gastrointest Dis,1998;9:21-30
  • 5[7]Geerling BJ,Badart-Smook A,van Deursen C,van Houwelingen AC,Russel MG,Stockbrugger RW,Brummer RJ.Nutritional supplementation with N-3fatty acids and antioxidants in patients with Crohn's disease in remission:effects on antioxidant status and fatty acid profile.Inflamm Bowel Dis,2000; 6:77 - 84
  • 6[8]Akobeng AK,Miller V,Stanton J.Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease.J Pediatr Gastroenterol Nutr ,2000;30:78 -84
  • 7[9]Hilsden RJ,Scott CM,Verhoef MJ.Complementary medicine use by patients with inflammatory bowel disease [see comments].Am J Gastroenterol,1998;93:697-701
  • 8[10]Clemett D,Markham A.Prolonged-release mesalazine:a review of its therapeutic potential in ulcerative colitis and Crohn's disease.Drugs,2000;59:929- 956
  • 9[11]Wahl C,Liptay S,Adler G.Sulfasalazine:a potent and specific inhibitor of nuclear factor kappa B.J Clin Invest,1998;101:1163 - 1174
  • 10[12]Irvine EJ,Greenberg GR,Feagan BG,Martin F,Sutherland LR,ThomsonAB,Nilsson LG,Persson T.Quality of life rapidly improves with budesonide therapy for active Crohn's disease.Canadian Inflammatory Bowel Disease Study Group.Inflamm Bowel Dis,2000; 6:181 - 187

同被引文献30

  • 1陈治水,危北海,张万岱.溃疡性结肠炎中西医结合诊治方案[J].世界华人消化杂志,2004,12(11):2690-2693. 被引量:47
  • 2诸琦,崔英.微生态疗法与炎症性肠病[J].中国实用内科杂志,2006,26(7):974-976. 被引量:23
  • 3许昌泰,王瑞玲,马连生.溃疡性结肠炎患者血清胃动素肽YYIgG和铁蛋白的研究[J].新消化病学杂志,1997,5(4):247-248. 被引量:8
  • 4Van Assche G,Dignass A,Panes J,et al. The second Eu- ropean evidence-hased consensns on tb.e diagnosis and management of CrohnJs disease:Definitions and diagnosis [J]. J Crohns Colitis,2010,4(1):7 27.
  • 5Murakami Y, Matsui T, Hirai F, et al. Efficacy of azathio- prine in mild or moderate relapse in Crohn's disease: clini- cal and endoscopic evaluation[J] Dig Endosc, 2010, 22 (1) :25-32.
  • 6Bernstein CN, Fried M, Krabshuis JH, et al. World Gas- troenterology Organization Practice Guidelines for the di- agnosis and management of IBD in 2010[J]. Inflamm Bowel Dis,2010,16(1) :112-124.
  • 7Hanauer SB,Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with6-mercap- topu-rine,mesalamine, or placebo : a 2-year trial [J]. Gas- troenterology, 2004,127 (3) : 723-729.
  • 8Akobeng AK,Zachos M. Tumor necrosis factor-alpha an tibody for induction of remission in Crohn's disease[J]. Cochrane Database Syst Rev, 2004 (1) : CD003574.
  • 9Li Y,Lopez R. Adalimumab therapy in Crohn's disease of the ileal pouch[J]. Inflamm Bowel Dis,2012,18(12) :2232-2239.
  • 10Papadakis KA. Safety and efficacy of ada limumab in Crohn's disease patients with an attenuated response to infliximab[J]. Gastroenterology, 2011,100 ( 1 ) : 75-79.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部